This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Frangou, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Frangou, S.
Advances in Psychiatric Treatment (2005) 11: 28-37
© 2005 The Royal College of Psychiatrists

Advancing the pharmacological treatment of bipolar depression

Sophia Frangou

Sophia Frangou is reader in psychiatry and Head of the Section of Neurobiology of Psychosis at the Institute of Psychiatry (PO Box 66, De Crespigny Park, London SE5 8AF, UK. Tel/fax: 020 7848 0903; e-mail: s.frangou{at}iop.kcl.ac.uk). Her research focuses on the pathophysiology and treatment of psychoses. Dr Frangou has received financial support from Sanofi-Synthelabo, GlaxoSmithKline and Bristol-Myers Squibb for conference attendance and consultancies and from AstraZeneca and Novartis for research.

Bipolar disorder is a recurring, often chronic, illness characterised by periods of mania and depression with variable inter-episode recovery. For the majority of patients it is the depressive component of this illness that contributes to most of the associated morbidity, social disability and mortality. Research and clinical experience suggest that acute treatment and prevention of depressive episodes is by far the most challenging aspect of the care of patients with the disorder. This review examines the contribution of depression to the course and outcome of bipolar disorder as well as diagnostic difficulties that often complicate treatment and may lead to inappropriate medication. Key studies that form the evidence base of treatment recommendation for bipolar depression are presented and areas of therapeutic uncertainty are highlighted.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
P. J. Cowen
New drugs, old problems: REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 19 - 27.
[Abstract] [Full Text] [PDF]